The FDA's announcement that the shortage of Eli Lilly's Zepbound and Mounjaro is resolved indicates a significant shift in the market dynamics, particularly impacting lower-cost knockoff drugs that have proliferated in their absence.
Lilly has heavily invested in manufacturing to boost the supply of its popular medications while emphasizing concerns over the quality of compounded versions, some of which have been found contaminated.
Despite the resolution of shortages, the complexity of the supply chain for refrigerated medicines means that patients may still face challenges finding specific doses in pharmacies.
Collection
[
|
...
]